MA55214A - Composés, compositions et procédés pour le traitement d'une maladie - Google Patents

Composés, compositions et procédés pour le traitement d'une maladie

Info

Publication number
MA55214A
MA55214A MA055214A MA55214A MA55214A MA 55214 A MA55214 A MA 55214A MA 055214 A MA055214 A MA 055214A MA 55214 A MA55214 A MA 55214A MA 55214 A MA55214 A MA 55214A
Authority
MA
Morocco
Prior art keywords
disease
compositions
treating
compounds
methods
Prior art date
Application number
MA055214A
Other languages
English (en)
Inventor
Subramanian Baskaran
Sreerupa Challa
Dillon Cleary
Rayomand H Gimi
Radhakrishnan P Iyer
Ron Mastrolia
Vishal Nair
Seetharamaiyer Padmanabhan
Anjaneyulu Sheri
Leena Praba Suppiah
Shenghua Zhou
Original Assignee
F Star Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Star Therapeutics Inc filed Critical F Star Therapeutics Inc
Publication of MA55214A publication Critical patent/MA55214A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA055214A 2019-03-05 2020-03-05 Composés, compositions et procédés pour le traitement d'une maladie MA55214A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814025P 2019-03-05 2019-03-05
US201962879178P 2019-07-26 2019-07-26

Publications (1)

Publication Number Publication Date
MA55214A true MA55214A (fr) 2022-01-12

Family

ID=72338059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055214A MA55214A (fr) 2019-03-05 2020-03-05 Composés, compositions et procédés pour le traitement d'une maladie

Country Status (21)

Country Link
US (1) US12667573B2 (fr)
EP (1) EP3934652A4 (fr)
JP (1) JP2022525010A (fr)
KR (1) KR20210135544A (fr)
CN (1) CN113645977A (fr)
AU (1) AU2020232761A1 (fr)
BR (1) BR112021017583A2 (fr)
CA (1) CA3131620A1 (fr)
CL (1) CL2021002294A1 (fr)
CO (1) CO2021012586A2 (fr)
CR (1) CR20210508A (fr)
DO (1) DOP2021000184A (fr)
EC (1) ECSP21073266A (fr)
IL (1) IL285782A (fr)
JO (1) JOP20210244A1 (fr)
MA (1) MA55214A (fr)
MX (1) MX2021010701A (fr)
PE (1) PE20220166A1 (fr)
PH (1) PH12021552084A1 (fr)
SG (1) SG11202109452SA (fr)
WO (1) WO2020181050A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (fr) 2016-09-29 2020-05-06 The Regents of the University of California Composés pour l'augmentation de la plasticité neuronale
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
EP3876939A4 (fr) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations
WO2020097396A1 (fr) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Dérivés de benzimidazole et dérivés d'aza-benzimidazole en tant qu'inhibiteurs de janus kinase 2 et leurs utilisations
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2020181050A1 (fr) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Composés, compositions et procédés pour le traitement d'une maladie
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
PH12022550709A1 (en) 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
CA3156828A1 (fr) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase tricycliques et leurs utilisations
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4192952A1 (fr) * 2020-08-10 2023-06-14 Novartis AG Traitements contre des maladies dégénératives de la rétine
CA3196620A1 (fr) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. Composes de 5- et 6-azaindole pour l'inhibition de tyrosine kinases bcr-abl
CN114478715B (zh) * 2020-10-26 2023-12-22 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达s2结构域蛋白的新型冠状病毒疫苗递呈系统及其应用
EP4267574B1 (fr) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN117321055A (zh) * 2021-03-18 2023-12-29 辉瑞公司 Sting(干扰素基因刺激剂)的调节剂
WO2022221415A2 (fr) 2021-04-13 2022-10-20 The Regents Of The University Of California Composés tétracycliques pour le traitement de troubles cérébraux
WO2022266711A1 (fr) * 2021-06-23 2022-12-29 Aculeus Therapeutics Pty Ltd Dimères d'amidobenzimidazole substitués en tant que modulateurs de sting
CA3234638A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
EP4626553A2 (fr) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Agonistes de tlr7 et conjugués anticorps-médicament associés
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas
CN115624616B (zh) * 2022-12-21 2023-03-14 上海市东方医院（同济大学附属东方医院） 接头蛋白pinch在诊断血管发育异常相关疾病中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6062590A (en) * 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
ATE307132T1 (de) 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
WO2008130581A1 (fr) 2007-04-20 2008-10-30 Schering Corporation Dérivées de pyrimidinone, et leurs méthodes d'utilisation
EP2324044A4 (fr) 2008-08-04 2012-04-25 Univ Miami Sting (stimulateur de gènes d interféron), un régulateur de réponses immunitaires innées
WO2010019392A1 (fr) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Dérivés de purine pour le traitement de la maladie d’alzheimer
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2870527A1 (fr) 2012-04-17 2013-10-24 Astellas Pharma Inc. Compose heterocyclique aromatique bicyclique azote
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
SG11201607586UA (en) 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3755331B1 (fr) 2018-02-21 2026-01-28 The Scripps Research Institute Agonistes de stimulateur de gènes d'interféron (sting) pour une utilisation dans le traitement du cancer
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
WO2020181050A1 (fr) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Composés, compositions et procédés pour le traitement d'une maladie

Also Published As

Publication number Publication date
CO2021012586A2 (es) 2021-10-20
CL2021002294A1 (es) 2022-04-01
MX2021010701A (es) 2022-02-21
US12667573B2 (en) 2026-06-30
CA3131620A1 (fr) 2020-09-10
CR20210508A (es) 2022-03-11
KR20210135544A (ko) 2021-11-15
PH12021552084A1 (en) 2022-05-30
IL285782A (en) 2021-10-31
CN113645977A (zh) 2021-11-12
EP3934652A4 (fr) 2022-12-07
PE20220166A1 (es) 2022-01-28
BR112021017583A2 (pt) 2021-11-09
EP3934652A1 (fr) 2022-01-12
US20220168309A1 (en) 2022-06-02
ECSP21073266A (es) 2021-11-30
WO2020181050A1 (fr) 2020-09-10
JOP20210244A1 (ar) 2023-01-30
SG11202109452SA (en) 2021-09-29
DOP2021000184A (fr) 2021-12-15
AU2020232761A1 (en) 2021-10-21
JP2022525010A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
EP3934652A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP4021500A4 (fr) Procédés pour le traitement d'une maladie oculaire thyroïdienne
EP4034167A4 (fr) Procédés et compositions pour le traitement d'une maladie ou d'un trouble
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
EP3773552A4 (fr) Composés permettant de traiter la maladie de huntington
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
EP3852735A4 (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
EP3986863A4 (fr) Inhibiteurs de glycolate oxydase pour le traitement d'une maladie
EP3914604A4 (fr) Compositions et procédés pour traiter, prévenir ou inverser une inflammation et des troubles associés à l'âge
IL287945A (en) Compounds for the treatment of Huntington's disease
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3976595A4 (fr) Composés de 1-oxo-isoindoline-5-carboxamide substitués, compositions de ceux-ci, et procédés de traitement associés
EP4025256A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP4085144A4 (fr) Compositions pour le traitement de l'ataxie de friedreich
EP4100404A4 (fr) Procédés et composés pour le traitement d'une maladie génétique
EP3955937A4 (fr) Composés et procédés pour le traitement de troubles oculaires
EP4291239A4 (fr) Composés, compositions et méthodes de traitement de maladies et d'états liés à l'âge
EP3877374A4 (fr) Procédés d'extraction, de traitement et de purification d'une famille sélectionnée de composés cibles à partir de cannabis
EP3820477A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP4034530A4 (fr) Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d'une maladie
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
EP4069309A4 (fr) Composés conjugués liant la sortiline, compositions et utilisations correspondantes pour le traitement d'un cancer
EP4153214A4 (fr) Méthodes et compositions pour le traitement d'une maladie fibrotique
EP3911329A4 (fr) Composition pour la prévention ou le traitement d'une maladie du foie métabolique